International experts recommend that children who want to be treated for bedwetting should be offered desmopressin or alarm therapy
Saint-Prex, Switzerland – 27 June, 2018 –
Guidelines Published in the June Issue of Journal of Urology
Ferring Pharmaceuticals, known for its commitment to paediatric health, is pleased to announce that the international medical community has published guidelines for treating children suffering from bedwetting (noctural enuresis).
Ferring has been a frontrunner with treatment of Primary Nocturnal Enuresis (PNE/bedwetting). The company’s product MINIRIN (Desmopressin) has been used successfully by millions of children for more than 30 years and is recommended by the World Health Organisation.
The International Children’s Continence Society (ICCS) published guidelines in the Journal of Urology (June issue) for managing nocturnal enuresis (bedwetting).1
The goals of this management strategy are:
- to make life more endurable for the child and his/her family
- to reduce the risk for life-long nocturnal enuresis
“Ferring is extremely pleased with these recommendations’, said Michel L. Pettigrew, COO. ‘Bedwetting affects millions of children world-wide. It can be successfully treated, we are glad that experts are recommending parents to seek help and ask their GP, health visitor or school nurse about the treatments available to them.”
Recommendations for Treating Bedwetting
Effective management of bedwetting can make an enormous difference to a child’s and parents’ life. Experts recommend that a child who wants to be treated for his/her bedwetting should be offered such treatment. The child should be older than 6 years before treatment is undertaken as younger children are rarely capable of investing the time and energy required to become dry.
While counseling the child on regular drinking and voiding habits can be successful – only 18% of children became dry using this approach.
For the greater majority of children, the ICCS recommends the first-line treatments of desmopressin therapy, alarm therapy or a combination of the two modalities. It is essential to seek the assistance of a doctor to decide which treatment would be best suited.
Desmopressin (MINIRIN) is a vasopressin analogue with profound antidiuretic activity.
Desmopressin reduces the number of wet nights by lowering night time urine production and is approved as first-line therapy in children with nocturnal polyuria and normal bladder function, which is the background in many cases. The benefits of desmopressin usually appear in a, weeks time resulting in rapid improvement in nocturnal enuresis.
A child wetting the bed should be offered sympathy and reassured that they are not at fault. Punishing the child is a counter-productive approach and will probably exacerbate the problem. Parents should chat about bedwetting with their doctor who will be able to give some advice on its possible cause and potential treatments.
Advice, support and help groups
For further information please visit www.ferring.com, www.MINIRIN.com.
About Ferring Pharmaceuticals
Ferring is a research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, infertility and urology.
In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.
To learn more about Ferring or our products please visit us at:
For more information, please contact
Ferring International Center
+45 28 78 72 09
- Hjalmas K et al. Nocturnal enuresis: an international evidence based management strategy. J Urol 2004;171:2545-2561.